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Dear Editor
Cancer is one of the most momentous and intricate 
life-threatening health problems which despite routine 
and combination treatments are still accompanied by high 
mortality worldwide (Gorgich et al., 2017). Because tumor 
cells have rapid and uncontrolled proliferation compare 
to normal cells, they need more nutrients, which in turn 
for supplying it begins to alter normal cellular signaling 
pathways and extensive angiogenesis in the specific 
tumor microenvironment (TME). During tumorigenesis, 
tumor cells undergo intra/extracellular specific biological 
changes as a result of increased metabolic requirements. 
These changes lead to overexpression of cell surface 
receptors, increased membrane channels and transporters 
(Heidari et al., 2017; Ancey et al., 2018). Based on these 
facts, diagnostic and therapeutic strategies can be designed 
for tumor-cells targeting.
Standard treatment of most tumors, particularly in the 
advanced stages, is based on multi-drug chemotherapy. 
Although this method initially provides considerable 
antitumor effects, in tumor progression, but often in 
continuation with the advent of limitations they are 
incapable of treating the tumor and can only increase the 
survival rate of patients. The most important hurdles of 
conventional treatment of tumors include physicochemical 
properties of drugs (poor solubility, high systemic toxicity 
and etc.), tumor heterogeneity, various tumorigenesis 
mechanisms, specific TME (pH, temperature and etc.), 
the presence of natural and tumor barriers, and interstitial 
tissue pressure in passive-tumor targeting method (Florea 
and Büsselberg, 2011; Bluthgen and Besse, 2015).
One promising strategy to overcom these obstacles 
is to use smart nanocarriers that have been approved by 
the FDA.
Recently, Park et al., (2021) designated a pH-sensitive 
multi-drug liposomes functionalized with folate receptor 
β (FRβ) for treatment of non-small cell lung cancer 
(NSCLC). They concluded that this platform with the 
ability to carry several drugs simultaneously, influence 
different aspects of tumorigenesis, with the least cytotoxic 
effects on off-target tissues and effective drug delivery 
to optimized dose. In addition, because of the use of 
pH-sensitive liposomes conjugated with FRβ which 
overexpressed in NSCLC cells, they directly targeted the 
TME and the tumor cells, respectively. 
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In another study, researchers developed a smart 
liposomes-based delivery system for the treatment 
of gliomas. Their findings showed that dual therapy 
(temozolomide and bromodomain inhibitor) by smarted 
liposomes with transferrin, effectively exerts therapeutic 
effects on different aspects of tumors with desirable 
dosing and reduces tumor burden up to 2-fold, compared 
to conventional therapy in tumor-bearing mice. Moreover, 
due to the utilization of targeted liposomes, cellular uptake 
of liposomes dramatically increases, which in turn protects 
non-target tissues from the systemic drug cytotoxicity 
(Lam et al., 2018). Thus, by designing this nano platform, 
they overcame many of the limitations of conventional 
drug delivery in the central nervous system (Lam et al., 
2018; Moradi et al., 2019). 
Hong et al., (2020) findings indicated that ginsenoside 
Rh2-liposomes with multifunctional properties, effectively 
accumulate in tumor site and increase cellular uptake via 
interaction between Rh2 and glucose transporter of 4T1 
breast tumor cells. Furthermore, Rh2-liposomes had a 
significant effect on controlling cancer progression by 
influencing the characteristics of the TME via remodel 
of the tumor structure and modulating immune responses.
According to the above-aforementioned, the 
application of targeted nanoparticles in accordance with 
the specific TME in each tissue can increase cellular 
uptake by target cells, thereby increasing the therapeutic 
efficiency and reducing toxicity in off-target tissues. 
Therefore, tumor-targeting by smart nanocarriers can be 
used as an ideal potential promising strategy to bypass 
the obstacles of conventional cancer treatments and even 
isolation of tumor cells.
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